Literature DB >> 22118954

Decreased sleep duration: a risk of progression of degenerative lumbar scoliosis.

Hao Li1, Chengzhen Liang, Chenchun Shen, Yan Li, Qixin Chen.   

Abstract

Degenerative lumbar scoliosis (DLS) is a spinal deformity that develops after skeletal maturity with a Cobb angle of more than 10° in the coronal plane. As the life expectancy of our population increases, DLS becomes a prevalent health issue affecting the quality of life of the elderly. The degree of the scoliosis curvature affects not only the symptoms but also the choice of treatments. Osteoporosis and intervertebral disc degeneration (IDD) have been suggested as two important risks associated with the progression of DLS. Interestingly, recent data implicate interleukin-1 (IL-1) in the altered matrix biology that characterizes human IDD. Compelling evidence links decreased sleep duration to lower bone mineral density (BMD) and elevated expression of IL-1. Based on these evidences, we propose that decreased sleep duration might be a risk of the progression of DLS, and hypothesize that the underlying mechanisms might be the elevated excretion of glucocorticoids and elevated expression of IL-1.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22118954     DOI: 10.1016/j.mehy.2011.10.036

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  2 in total

1.  Factors associated with scoliosis in schoolchildren: a cross-sectional population-based study.

Authors:  Marina Pegoraro Baroni; Geronimo José Bouzas Sanchis; Sanderson José Costa de Assis; Rafael Gomes dos Santos; Silvana Alves Pereira; Klayton Galante Sousa; Johnnatas Mikael Lopes
Journal:  J Epidemiol       Date:  2015-01-19       Impact factor: 3.211

2.  Morphology and epidemiological study of idiopathic scoliosis among primary school students in Chaozhou, China.

Authors:  Zemin Cai; Ruibin Wu; Shukai Zheng; Zhaolong Qiu; Kusheng Wu
Journal:  Environ Health Prev Med       Date:  2021-07-03       Impact factor: 3.674

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.